Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix

Medical Hypotheses

Volumn 71, Issue 3, 2008, Pages 374-378

  Han, Daqing ^a   Liu, Weiqiang ^a   Ao, Qiang ^a   Wang, Guangzhi ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COAGULATING AGENT; FIBRIN; FIBRIN GLUE; FIBRINOGEN; FIBRONECTIN; HEPARIN; MATRIX METALLOPROTEINASE; PLASMIN;

ARTICLE; BLOOD CLOT; BONE TISSUE; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; MAST CELL; PRIORITY JOURNAL; TISSUE REPAIR; TISSUE STRUCTURE;

BONE MORPHOGENETIC PROTEINS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX PROTEINS; FIBRIN; FIBRONECTINS; HEPARIN; HUMANS; ORTHOPEDIC PROCEDURES;

EID: 47549102735     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.01.035     Document Type: Article

References (28)

1. Smoljanović T., Grgurević L., and Jelić M. Regeneration of the skeleton by recombinant human bone morphogenetic proteins. Coll Antropol 3 (2007) 923-932
2. Groeneveld E.H., and Burger E.H. Bone morphogenetic proteins in human bone regeneration. Eur J Endocrinol 142 (2000) 9-21
3. Lieberman J.R., Daluiski A., and Einhorn T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84 (2002) 1032-1044
4. Kwon B., and Jenis L.G. Carrier materials for spinal fusion. Spine J 5 (2005) 224S-230S
5. Gupta M.C., and Maitra S. Bone grafts and bone morphogenetic proteins in spine fusion. Cell Tissue Bank 3 (2002) 255-267
6. Geiger M., Li R.H., and Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 55 (2003) 1613-1629
7. Friess W., Uludag H., Foskett S., Biron R., and Sargeant C. Characterization of absorbable collagen sponges as rhBMP-2 carriers. Int J Pharm 187 (1999) 91-99
8. Carlisle E., and Fischgrund J.S. Bone morphogenetic proteins for spinal fusion. Spine J 5 (2005) 240S-249S
9. Gautschi O.P., Frey S.P., and Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 77 (2007) 626-631
10. Giannoudis P.V., Kanakaris N.K., and Einhorn T.A. Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence. Osteoporos Int 18 (2007) 1565-1581
11. Robinson Y., Heyde C.E., Tschöke S.K., Mont M.A., Seyler T.M., and Ulrich S.D. Evidence supporting the use of bone morphogenetic proteins for spinal fusion surgery. Expert Rev Med Dev 5 (2008) 75-84
12. Meikle M.C. On the transplantation, regeneration and induction of bone: the path to bone morphogenetic proteins and other skeletal growth factors. Surgeon 5 (2007) 232-243
13. De Long Jr. W.G., Einhorn T.A., and Koval K. Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am 89 (2007) 649-658
14. Magnusson M.K., and Mosher D.F. Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol 18 (1998) 1363-1370
15. Davis G.E., Bayless K.J., Davis M.J., and Meininger G.A. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol 156 (2000) 1489-1498
16. Pankov R., and Yamada K.M. Fibronectin at a glance. J Cell Sci 115 (2002) 3861-3863
17. Corbett S.A., Lee L., Wilson C.L., and Schwarzbauer J.E. Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. J Biol Chem 272 (1997) 24999-25005
18. Powell A.K., Yates E.A., Fernig D.G., and Turnbull J.E. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 14 (2004) 17R-30R
19. Lutolf M.P., Lauer-Fields J.L., and Schmoekel H.G. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci USA 100 (2003) 5413-5418
20. Sakiyama-Elbert S.E., and Hubbell J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 65 (2000) 389-402
21. Takada T., Katagiri T., Ifuku M., et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 278 (2003) 43229-43235
22. Jeon O., Song S.J., Kang S.W., Putnam A.J., and Kim B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(l-lactic-co-glycolic acid) scaffold. Biomaterials 28 (2007) 2763-2771
23. Ruppert R., Hoffmann E., and Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237 (1996) 295-302
24. Zhao B., Katagiri T., and Toyoda H. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 281 (2006) 23246-23253
25. Greiling D., and Clark R.A. Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. J Cell Sci 110 (1997) 861-870
26. Bick R.L., Frenkel E.P., Walenga J., Fareed J., and Hoppensteadt D.A. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am 19 (2005) 1-51
27. Le Nihouannen D., Guehennec L.L., and Rouillon T. Micro-architecture of calcium phosphate granules and fibrin glue composites for bone tissue engineering. Biomaterials 27 (2006) 2716-2722
28. Abraham L.A., Jenkins A.L., Stone S.R., and Mackie E.J. Expression of the thrombin receptor in developing bone and associated tissues. J Bone Miner Res 13 (1998) 818-827